Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07391098

Peripheral Perfusion and Outcomes in ICU Patients With Sepsis

People with sepsis who are treated in the intensive care unit (ICU) often have impaired blood flow to the skin and other tissues. These alterations in tissue perfusion may be associated with disease severity and clinical outcomes.

The aim of this study is to see whether simple signs of blood flow to the skin, such as capillary refill time and blood test measurements, are linked to outcomes in people with sepsis treated in the ICU.

Adults with sepsis who are admitted to the ICU will be invited to take part. Researchers will collect routine clinical data and blood test results during the first day of ICU treatment. No extra procedures or treatments will be performed as part of the study.

The results of this study may improve understanding of early signs of impaired circulation in sepsis and their relation with recovery and survival.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Emergebcy Clinical County Hospital - Intensive Care Clinic

Târgu Mureş, Mureș County, 540136, Romania

Location contact

Alexandra Elena Lazăr

CONTACT

[email protected]

0737067900

About this study

Sepsis is a life-threatening condition caused by a dysregulated host response to infection and is associated with high morbidity and mortality in intensive care units (ICUs). Early detection of impaired tissue perfusion is essential for risk stratification and may help predict clinical outcomes.

Peripheral perfusion can be assessed using a combination of bedside clinical signs and physiological and biochemical markers. Capillary refill time (CRT) is a simple, non-invasive bedside measure of peripheral perfusion. In addition, respiratory and blood gas-derived variables, such as end-tidal carbon dioxide (ETCO₂) and the veno-arterial carbon dioxide difference (ΔCO₂), may reflect alterations in tissue blood flow and microcirculatory dysfunction. However, the relationship between these markers and clinical outcomes in patients with sepsis is not fully established.

This is a prospective observational cohort study conducted in adult ICU patients with sepsis or septic shock. Eligible participants will be enrolled after ICU admission. Sepsis will be defined according to Sepsis-3 criteria, with a Sequential Organ Failure Assessment (SOFA) score of 2 or higher at inclusion. Baseline disease severity will be further assessed using the Acute Physiology And Chronic Health Evaluation (APACHE) IV score.

Peripheral perfusion markers will be recorded at predefined time points: at inclusion (T0), six hours (T6), and twenty-four hours (T24). CRT and ETCO₂ will be measured at the bedside, using standardized methods. Arterial and venous blood gas samples will be obtained at the same time points to determine PaCO₂, PvCO₂, lactate levels, and the veno-arterial carbon dioxide difference (ΔCO₂). Blood sampling will be performed through existing arterial or venous catheters whenever possible.

Additional routinely collected clinical data will include hemodynamic variables, ventilatory parameters, vasopressor use, and organ support. Outcomes will include SOFA score on day three, ventilator-free days and vasopressor-free days within the first seven days, and vital status at day 7 and day 28.

No experimental treatments or protocol-driven changes to standard clinical management will be introduced. This study aims to evaluate the association between early peripheral perfusion markers-combining CRT, ETCO₂, and blood gas-derived variables-and short-term outcomes in adults with sepsis treated in the ICU.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adults aged 18 years or older
  • admission to the intensive care unit
  • sepsis or septic shock, defined according to Sepsis-3 criteria
  • SOFA score ≥ 2 at inclusion
  • presence of an arterial line and a central venous catheter suitable for blood sampling
  • possibility to perform peripheral perfusion assessment (CRT) at predefined time points

Exclusion criteria

  • age under 18 years
  • pregnancy
  • expected ICU stay less than 24 hours
  • limitations of therapy at ICU admission (e.g., DNR or comfort-only care)
  • improper central venous catheter position (catheter tip not located in the superior vena cava)
  • absence of arterial or central venous access required for paired blood gas sampling
  • refusal of consent, when applicable according to local ethics requirements

Treatment and study plan

PERIPHERAL PERFUSION EVALUATION

Other

This intervention consists of a predefined, multimodal peripheral perfusion assessment combining bedside clinical evaluation and blood gas analysis. Capillary refill time is measured at standardized time points, together with concurrent end-tidal carbon dioxide recording. Paired arterial and venous blood gas samples are obtained at the same time points to calculate the veno-arterial carbon dioxide difference and assess lactate levels. The intervention is limited to repeated physiological measurements during the first 24 hours of ICU admission and does not include any therapeutic intervention or protocol-driven change in clinical management

Primary outcomes

  1. Change in Sequential Organ Failure Assessment (SOFA) score from inclusion (day 0) to day 3.

    Time frame: From enrollemnt to day 3

    The SOFA score ranges from 0 to 24, with higher scores indicating greater organ dysfunction and worse clinical status.

    The change score is calculated as SOFA score at day 3 minus SOFA score at inclusion, with positive values indicating worsening organ dysfunction and negative values indicating improvement.

Secondary outcomes

  1. Ventilator-Free Days (0-7)

    Time frame: first 7 days

    Ventilator-free survival days from day 0 to day 7, with death before day 7 assigned a value of 0.

  2. Vasopressor-Free Days (0-7)

    Time frame: first 7 days

    Vasopressor-free survival days from day 0 to day 7 (death before day 7 scored as 0).

  3. Vital Status on Day 7

    Time frame: first 7 days

    Survivor or non-survivor at day 7 after ICU admission.

  4. Vital Status on Day 28

    Time frame: first 28 days

    Survivor or non-survivor at day 28 after ICU admission.

Study contacts

Contact information is provided by the study sponsor or research team.

Alexandra Elena Lazăr, Consultant, Assoc prof

CONTACT

[email protected]

+40737067900

Sponsors and collaborators

Lead sponsor

Alexandra Elena Lazăr

Other

Registry information

Official study title

Peripheral Perfusion and Outcomes in ICU Patients With Sepsis (PERFUSE-ICU)

Acronym: PERFUSE-ICU

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 5, 2026
Registry last updated
Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.